BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Religare maintains hold on Dr. Reddy's Laboratories
We expect FY17 to be a muted year for Dr Reddy's given the high product concentration risk in the US, incremental competition, lack of Venezuela sales and a weak domestic business. We expect the growth momentum to pick up from FY18 onwards on a weak base and potential resolution of the warning letter on key facilities.